A biotech stock trading below cash can look like a straightforward bargain: buy the shares for less than the money on the balance sheet and receive the drug pipeline at no cost. That interpretation skips several steps. The cash may be months out of date, some funds may be restricted, and development spending can consume the apparent discount before shareholders receive any benefit. Market capitalisation and enterprise value help separate the price of the equity from the value implied for the operating business. Within biotech financial analysis and valuation, these measures provide a starting point for assessing what investors are paying, which obligations sit ahead of them, and how much financial protection the cash actually provides.
Market capitalisation measures the price of the common equity
Market capitalisation equals the share price multiplied by common shares outstanding. A hypothetical biotech with 100 million shares trading at $1.20 has a market capitalisation of $120 million. This measures the market value of its common equity, rather than the value of its laboratories, drug candidates or cash in isolation. Share price alone says little about valuation. A company trading at $2 can have a higher market capitalisation than one trading at $20 if it has enough shares outstanding. Use the full outstanding share count, not the public float, which excludes certain holdings and measures a different thing.
The denominator needs attention. The weighted average share count used to calculate earnings per share describes a reporting period; it may differ from the shares outstanding on the valuation date. Check subsequent offerings, warrant exercises and other changes after quarter end. Options, restricted stock awards and convertible instruments require a separate assessment of potential ownership claims. Do not assume the diluted earnings per share denominator captures every instrument that matters to valuation. The treatment of share dilution and equity offerings becomes particularly relevant when a company has raised money since its last balance sheet.
Enterprise value separates operating value from financing
Enterprise value, or EV, adjusts equity value for cash and financing claims. A simple screening formula is:
Enterprise value = market capitalisation + debt − cash and cash equivalents.
For a biotech holding liquid investments, an expanded calculation can subtract eligible marketable securities too. Preferred equity and noncontrolling interests may require adjustments where present. The purpose is to estimate the value the market assigns to operating assets after separating out financial assets and claims. Cash is subtracted because the equity price already reflects shareholders’ interest in it; debt is added because common equity represents only one source of financing. These distinctions are set out in NYU Stern’s enterprise value definitions. State the convention used, since two data providers can produce different EV figures from the same financial statements.
Consider the following hypothetical company. All amounts are in US dollars, and the cash and securities are assumed to be unrestricted and readily realisable.
| Input or calculation | Amount |
|---|---|
| Common shares outstanding | 100 million |
| Share price | $1.20 |
| Market capitalisation | $120 million |
| Cash and cash equivalents | $80 million |
| Eligible marketable securities | $100 million |
| Total eligible cash and investments | $180 million |
| Debt | $20 million |
| Net cash: eligible cash and investments less debt | $160 million |
| Enterprise value: $120 million + $20 million − $180 million | −$40 million |
The company trades below both its gross cash and investments of $180 million and its net cash of $160 million. Gross cash per share is $1.80; net cash per share, $1.60. Neither figure is a promised distribution. Also, “below cash” does not always mean negative enterprise value. Another company with a $120 million market capitalisation, $150 million in eligible cash and $60 million of debt trades below gross cash but has positive EV of $30 million. The distinction matters. A screen comparing market capitalisation with cash alone can make a debt burden disappear from view.
Decide which cash and obligations belong in the calculation
Start with the balance sheet and investment notes rather than a headline cash figure. Cash equivalents and marketable securities are separate line items in many financial statements. Adding a reported combined liquidity figure to the individual components would count the same assets twice. Assess investments by their liquidity, credit quality and restrictions; their classification as current or noncurrent does not answer every valuation question. A liquid government security differs from an equity stake in another private biotech. The latter needs its own valuation and should not be treated as cash at its original purchase price.
Restricted cash needs separate treatment because shareholders cannot assume it is available to finance trials, repay unrelated creditors or fund a distribution. Identify the restriction and the conditions for release. Prepaid research expenses, receivables and tax assets are not interchangeable with cash either. They may carry economic value, but their recoverability and timing require separate assumptions. Record these adjustments alongside the original balance sheet figures so another reader can reproduce the calculation. A consistent process for researching financial filings and other biotech evidence helps prevent a convenient headline number from replacing the underlying accounts.
On the claims side, distinguish financing debt from ordinary operating liabilities. Accounts payable and accrued trial expenses are not automatically added to standard EV as debt, although they matter when forecasting spending or estimating liquidation proceeds. Lease treatment should match the valuation model and peer comparison. Convertible securities require particular care: treating an instrument as both outstanding debt and converted equity counts the claim twice. For a distressed borrower, accounting carrying value may also differ from the amount needed to settle a loan. Review the terms of debt, convertibles and royalty financing, including repayment premiums, collateral and minimum cash requirements.
Bring reported cash forward to the valuation date
A live share price combined with an old cash balance produces a mixed-date valuation. Return to the hypothetical company with $180 million of eligible cash and investments. Suppose three months have passed since quarter end and estimated cash consumption has been $8 million a month, with no financing or other material flows. Estimated cash is now $156 million. Holding market capitalisation and debt unchanged, EV rises from negative $40 million to negative $16 million. Most of the apparent discount has disappeared without any change in the share price. This roll-forward is an estimate, so show the spending assumption and valuation date rather than presenting it as reported cash.
Use cash flow rather than net loss as the starting point for estimating depletion. Noncash charges and payment timing can create large differences between accounting losses and cash consumption. The SEC’s guide to financial statements distinguishes operating cash flows from investing and financing flows. That separation matters when a company sells securities from its investment portfolio: moving money from investments into a bank account does not replenish combined cash and investments. Financing does replenish liquidity, but it is not evidence that operating spending has slowed. Detailed forecasting belongs in the assessment of cash burn and cash runway; the EV calculation needs its output.
Sana Biotechnology provides a historical illustration of the difference between cash depletion and operating cash use. At December 31, 2025, it reported $138.4 million of cash, cash equivalents and marketable securities, down from $152.5 million a year earlier. The $14.1 million decline sat alongside $143.8 million of cash used in operations, with $126.4 million of net equity financing proceeds offsetting much of that use. Those figures appear in Sana’s full year 2025 financial results, published March 3, 2026. This illustrates cash reconciliation, not whether Sana traded below cash. Comparing the two year-end balances alone would have given a poor measure of the cost of running the business.
Why a biotech can have negative enterprise value
Negative EV is a market signal, not a valuation verdict. It can reflect an expectation that management will spend more cash than the remaining programmes are worth. Consider a company whose lead trial has failed but which intends to fund several earlier candidates. Investors might assign positive value to those candidates while still expecting future research spending and corporate overhead to exceed that value. The operating business can then have a negative net value even though individual assets are worth something. Describing the pipeline as “free” hides the cost of keeping it alive. A pipeline is not a finished product sitting on a shelf.
The timing of evidence matters as much as the balance. A company funded through a meaningful clinical result presents a different proposition from one that needs financing before the result arrives. Assess the spending required to reach the next event, the quality of the evidence it could produce, and the options available after an unfavourable outcome. The relationship between cash and clinical, regulatory and partnership catalysts determines whether the company can test its investment case before its financial cushion erodes. A negative EV screen cannot establish whether management’s next dollar of spending is likely to create value.
Test the discount against future spending
The hypothetical company now has estimated cash and investments of $156 million. Assume it continues consuming $8 million a month, with no financing, no change in debt and a constant $120 million market capitalisation. The table isolates the effect of cash spending. It is a mechanical sensitivity, not a share price forecast.
| Valuation point | Eligible cash and investments | Enterprise value |
|---|---|---|
| Current estimate | $156 million | −$16 million |
| After six further months | $108 million | $32 million |
| After nine further months | $84 million | $56 million |
At that spending rate, the current negative EV disappears after two months. The clinical programme might become more valuable during that period, or less valuable. Cash arithmetic alone cannot tell you which. Its job is to expose how quickly the initial balance sheet discount can vanish and how much progress the business needs to make in return.
Cash per share is not a liquidation floor
Shareholders own an interest in a company, not a right to withdraw their proportion of its bank balance on demand. A liquidation estimate must account for claims and closure costs before considering a distribution to common equity. In US bankruptcy proceedings, common shareholders rank behind creditors, and existing shares can be cancelled during reorganisation; the SEC investor bulletin on public company bankruptcy sets out that risk. Trading below cash does not itself mean a company is insolvent. It does mean that a proposed cash floor needs a claims analysis rather than a division of cash by shares.
As an alternative to continued development, assume the hypothetical company shuts down with $156 million of eligible cash and investments. Deduct $20 million of debt, $12 million of existing payables and accruals, $24 million of additional closure costs, and a $10 million contingency reserve. The model leaves $90 million, or $0.90 per share, before discounting for the time taken to distribute it. That is below the $1.20 share price. These are illustrative assumptions, not standard liquidation deductions. The closure costs must exclude amounts already captured in payables, and the reserve must not duplicate identified liabilities. Potential asset sale proceeds also need realistic estimates, rather than automatic credit at book value.
Contract terms can change the outcome. A programme sale may require payments to a licensor, while stopping development may end future milestones but leave termination obligations intact. A contingent milestone liability recorded for accounting purposes is not necessarily a cheque payable immediately at its carrying value. Read the triggers, settlement terms and survival clauses. The economics of licensing payments, milestones and royalties belong in the relevant operating or exit scenario, with each obligation counted once. A laboratory asset, a patent portfolio and a licensed drug candidate can have very different saleability.
Connect enterprise value to pipeline valuation without double counting
Market-implied EV and an independently estimated operating value answer different questions. The former shows the price implied by current trading and balance sheet adjustments; the latter asks what the programmes and business could be worth. Compare them using a model that includes future development costs, commercial spending and corporate overhead where relevant. A risk-adjusted net present value model can help organise those assumptions. A low EV does not validate a scientific thesis, and an attractive drug candidate does not establish that the common equity is cheap. The financing claims and cost of reaching commercial value remain part of the calculation.
When operating value already includes future development cash outflows, do not subtract those same outflows again from current cash. The equity bridge generally adds separately valued cash and other nonoperating assets to operating value, then subtracts debt and other relevant claims. The treatment depends on which cash flows the model has already valued, as detailed in NYU Stern’s treatment of cash and other equity valuation claims. Keep the bridge explicit. Otherwise a model can penalise spending twice, add the same investment twice, or treat corporate overhead as somebody else’s problem.
New financing also changes the calculation without necessarily changing operating value. If shares are issued at the prevailing price, with the share price unchanged and ignoring fees, market capitalisation and cash increase by the same amount. EV is mechanically unchanged. Existing holders nevertheless own a smaller percentage of the company, and discounts or warrants can alter the economics. Similarly, repaying debt with cash reduces both balances; it does not automatically create operating value. These transactions explain why a rising cash balance, a lower share count after a reverse split, or a larger market capitalisation should never be interpreted in isolation.
Build a worksheet that can be updated after each event
Keep reported facts separate from estimates. A useful worksheet records the share price timestamp, the date of the share count, the balance sheet date and each subsequent cash adjustment. Maintain separate outputs for headline EV, adjusted EV and estimated liquidation proceeds. They are different measures and should retain different labels. Where debt values or investment recoveries are uncertain, show the effect of changing them rather than burying an optimistic assumption in a single number. The same discipline used for testing biotech valuation assumptions applies to the cash bridge.
Set update triggers around events that change the inputs: financing completion, a programme termination, a revised spending plan or a transaction announcement. After a trial failure, for example, an old burn estimate may overstate future research spending while understating near-term severance and trial closure payments. After an offering, the old share count and old cash balance may both be wrong. Recalculate them together. Record what changed, which amounts remain estimates, and when another filing or payment should resolve the uncertainty.